Tirzepatide for Heart Failure and Obesity
- PMID: 40267439
- DOI: 10.1056/NEJMc2502743
Tirzepatide for Heart Failure and Obesity
Comment on
-
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16. N Engl J Med. 2025. PMID: 39555826 Clinical Trial.
Similar articles
-
Tirzepatide: First Approval.Drugs. 2022 Jul;82(11):1213-1220. doi: 10.1007/s40265-022-01746-8. Drugs. 2022. PMID: 35830001 Review.
-
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.EClinicalMedicine. 2024 Aug 15;75:102777. doi: 10.1016/j.eclinm.2024.102777. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39246719 Free PMC article.
-
Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials.Curr Obes Rep. 2024 Dec;13(4):739-742. doi: 10.1007/s13679-024-00592-x. Epub 2024 Oct 8. Curr Obes Rep. 2024. PMID: 39378016 Free PMC article. Review.
-
Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States.J Manag Care Spec Pharm. 2025 May;31(5):441-450. doi: 10.18553/jmcp.2025.31.5.441. J Manag Care Spec Pharm. 2025. PMID: 40298310 Free PMC article.
-
Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity.Am J Ther. 2023 Jul-Aug 01;30(4):e347-e352. doi: 10.1097/MJT.0000000000001643. Am J Ther. 2023. PMID: 37449929
Publication types
LinkOut - more resources
Full Text Sources